Ivan Labat - AGE Old Chief Information Officer
| AGEDelisted Stock | USD 0.74 0.01 1.37% |
Executive
Mr. Ivan Labat, Ph.D., is Chief Information Officer of the Company. Labat, Ph.D., is a veteran of research and development of genome informatics. Over the last 25 years, he has held several biotech industry leadership positions in design, development and implementation of the nextgeneration DNA sequencing methods and data analysis and curation. Ivan has received his M. S. in Molecular Biology and Physiology, and Ph. D. in Molecular Biology from the University of Belgrade.
| Professional Marks | Ph.D |
| Phone | 510 671 8370 |
| Web | https://www.agexinc.com |
AGE Old Management Efficiency
The company has Return on Asset of (0.8188) % which means that on every $100 spent on assets, it lost $0.8188. This is way below average. AGE Old's management efficiency ratios could be used to measure how well AGE Old manages its routine affairs as well as how well it operates its assets and liabilities.AGE Old has 4.37 M in debt with debt to equity (D/E) ratio of 0.75, which is OK given its current industry classification. AGE Old has a current ratio of 0.19, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for AGE to invest in growth at high rates of return.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Harold Waitz | Lineage Cell Therapeutics | 83 | |
| Jill JD | Invivyd | 52 | |
| Gloria Cosgrove | Lyra Therapeutics | N/A | |
| Robert Allen | Invivyd | 56 | |
| Bonne MBA | Inhibrx | 48 | |
| Jeffrey Himmelreich | MAIA Biotechnology | 50 | |
| Roee Shahar | Immunome | N/A | |
| Jeffrey Cole | Cadrenal Therapeutics, Common | N/A | |
| Robert MD | Lyra Therapeutics | N/A | |
| Jack Higgins | Immunome | 45 | |
| Julie MBA | Invivyd | 50 | |
| John Tilton | Biohaven Pharmaceutical Holding | 57 | |
| Robert MD | Immunome | 64 | |
| Jennifer Porcelli | Biohaven Pharmaceutical Holding | N/A | |
| Steven Dworetzky | Biohaven Pharmaceutical Holding | N/A | |
| Timothy Lee | Invivyd | N/A | |
| Josep Garcia | Inhibrx | N/A | |
| Saurabh Sewak | Foghorn Therapeutics | N/A | |
| John Berman | Larimar Therapeutics | N/A | |
| JD III | Lineage Cell Therapeutics | 44 | |
| Richard MD | Lyra Therapeutics | 61 | |
Management Performance
| Return On Asset | -0.82 |
AGE Old Leadership Team
Elected by the shareholders, the AGE Old's board of directors comprises two types of representatives: AGE Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AGE. The board's role is to monitor AGE Old's management team and ensure that shareholders' interests are well served. AGE Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AGE Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| EunJae CPA, Chief Officer | ||
| Alfred Kingsley, Chairman of the Board | ||
| Judith Segall, Secretary | ||
| Michael West, Chief Executive Officer, Founder, Director | ||
| Aubrey Grey, Vice President - New Technology Discovery | ||
| Gregory Bailey, Independent Chairman of the Board | ||
| Ivan Labat, Chief Information Officer | ||
| Joanne Hackett, Interim Board | ||
| Hal Sternberg, Vice President - Research | ||
| Nafees MD, Chief Officer | ||
| Andrea Park, Chief Financial Officer | ||
| Annalisa Jenkins, Independent Director | ||
| Michael May, Independent Director |
AGE Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AGE Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.82 | |||
| Operating Margin | (63.57) % | |||
| Current Valuation | 33.33 M | |||
| Shares Outstanding | 2.5 M | |||
| Shares Owned By Insiders | 75.73 % | |||
| Shares Owned By Institutions | 5.64 % | |||
| Number Of Shares Shorted | 4.47 K | |||
| Price To Earning | (5.95) X | |||
| Price To Book | 12.96 X | |||
| Price To Sales | 221.90 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in AGE Stock
If you are still planning to invest in AGE Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AGE Old's history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |